Diaz Paul J's Form 4 filing
Myriad Genetics Inc (MYGN) · filed May 15, 2024
- Accession no.
- 0001628280-24-023653
- Filed
- May 15, 2024
- Trade date
- May 13-15, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $5.73M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Diaz Paul JCIK 0001194247 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 13, 2024 | Common Stock | SSaleDisposed | −57,844 | $25.13 | −$1,453,619.72 | 1,236,166 | Direct | |
| May 14, 2024 | Common Stock | SSaleDisposed | −95,000 | $25.21 | −$2,394,950 | 1,141,166 | Direct | |
| May 15, 2024 | Common Stock | SSaleDisposed | −75,000 | $25.07 | −$1,880,250 | 1,066,166 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.